Phase i dose-escalation study to examine the safety and tolerability of LY2603618, a checkpoint 1 kinase inhibitor, administered 1 day after pemetrexed 500 mg/m2 every 21 days in patients with cancer

Investigational New Drugs

Volumn 31, Issue 1, 2013, Pages 136-144

  Weiss, Glen J ^a   Donehower, Ross C ^b   Iyengar, Tara ^a   Ramanathan, Ramesh K ^a   Lewandowski, Karen ^a   Westin, Eric ^c   Hurt, Karla ^c   Hynes, Scott M ^c   Anthony, Stephen P ^a   McKane, Scott ^d  

^a HonorHealth and the Scottsdale Lincoln Health Network   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c ELI LILLY AND COMPANY   (United States)

^d PharmaNet/i3   (United States)

Author keywords

Cancer; Checkpoint kinase inhibitor; LY2603618; Pemetrexed

Indexed keywords

CHECKPOINT KINASE 1 INHIBITOR; PEMETREXED; PROTEIN SERINE THREONINE KINASE INHIBITOR; RABUSERTIB; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BLOOD PRESSURE; BONE MARROW DISEASE; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER OF UNKNOWN PRIMARY SITE; CLINICAL ARTICLE; COLON CANCER; DIARRHEA; DISTRIBUTION VOLUME; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG FEVER; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; EOSINOPHIL COUNT; FATIGUE; FEMALE; GASTROESOPHAGEAL CARCINOMA; GASTROINTESTINAL HEMORRHAGE; HEMATOLOGIC DISEASE; HUMAN; HYPERTENSION; INFUSION RELATED REACTION; KIDNEY PAPILLARY CARCINOMA; LEUKOCYTE COUNT; LEUKOPENIA; LUNG INFECTION; LUNG NON SMALL CELL CANCER; LYMPHOCYTOPENIA; MALE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; NEUTROPHIL COUNT; OPEN STUDY; OVARY CANCER; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; RECTUM CANCER; SALIVARY GLAND CANCER; SIDE EFFECT; SMALL INTESTINE CANCER; SOLID TUMOR; TACHYCARDIA; TACHYPNEA; THROMBOCYTOPENIA; UTERINE CERVIX CANCER; WHEEZING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; GLUTAMATES; GUANINE; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS; PHENYLUREA COMPOUNDS; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; PYRAZINES;

EID: 84873100369     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-012-9815-9     Document Type: Article

References (21)

1. Miller KD, Picus J, Blanke C et al (2000) Phase II study of the multitargeted antifolate LY231514 (ALIMTA, MTA, pemetrexed disodium) in patients with advanced pancreatic cancer. Ann Oncol 11:101-103
2. Sanchez Y, Wong C, Thoma RS et al (1997) Conservation of the Chk1 checkpoint pathway in mammals: linkage of DNA damage to Cdk regulation through Cdc25. Science 277:1497-1501
3. Karnitz LM, Flatten KS, Wagner JM et al (2005) Gemcitabine-induced activation of checkpoint signaling pathways that affect tumor cell survival. Mol Pharmacol 68:1636-1644
4. Liu Q, Guntuku S, Cui XS et al (2000) Chk1 is an essential kinase that is regulated by Atr and required for the G(2)/M DNA damage checkpoint. Genes Dev 14:1448-1459
5. Morgan MA, Parsels LA, Parsels JD, Mesiwala AK, Maybaum J, Lawrence TS (2005) Role of checkpoint kinase 1 in preventing premature mitosis in response to gemcitabine. Cancer Res 65:6835-6842
6. Zhao H, Watkins JL, Piwnica-Worms H (2002) Disruption of the checkpoint kinase 1/cell division cycle 25A pathway abrogates ionizing radiation-induced S and G2 checkpoints. Proc Natl Acad Sci USA 99:14795-14800
7. Dai Y, Grant S (2010) New insights into checkpoint kinase 1 in the DNA damage response signaling network. Clin Cancer Res 16:376-383
8. Tonkinson JL, Marder P, Andis SL et al (1997) Cell cycle effects of antifolate antimetabolites: implications for cytotoxicity and cytostasis. Cancer Chemother Pharmacol 39:521-531
9. Tonkinson JL, Worzalla JF, Teng CH, Mendelsohn LG (1999) Cell cycle modulation by a multitargeted antifolate, LY231514, increases the cytotoxicity and antitumor activity of gemcitabine in HT29 colon carcinoma. Cancer Res 59:3671-3676
10. Merry C, Fu J, Wang J, Yeh I-Ju, Zhang Y (2010) Targeting the checkpoint kinase Chk1 in cancer therapy. Cell Cycle 9:279-283
11. Tse AN, Carvajal R, Schwartz GK (2007) Targeting checkpoint kinase 1 in cancer therapeutics. Clin Cancer Res 13:1955-1960
12. Marshall M, Barda D, Barnard D et al (2009) Characterization and preclinical development of LCI-1, a selective and potent Chk1 inhibitor in phase I clinical trials. Mol Cancer Ther 8(12 suppl 1):B248
13. Van Triest B, Pinedo HM, Giaccone G, Peters GJ (2000) Downstream molecular determinants of response to 5-fluorouracil and antifolate thymidylate synthase inhibitors. Ann Oncol 11:385-391
14. Giovannetti E, Honeywell R, Hanauske AR et al (2010) Pharmacological aspects of the enzastaurin-pemetrexed combination in non-small cell lung cancer (NSCLC). Curr Drug Targets 11:12-28
15. Marshall M, Barnard D, Diaz B et al. (2010) Evaluation of the antitumor activity of pemetrexed in combination with the Chk1 inhibitor LY2603618. Poster presented at 22nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, Berlin, Germany, Abstract No. 201
16. Hanauske AR, Lahn M, Musib LC et al (2009) Phase Ib safety and pharmacokinetic evaluation of daily and twice daily oral enzastaurin in combination with pemetrexed in advanced/metastatic cancer. Ann Oncol 20:1565-1575
17. Rollins KD, Lindley C (2005) Pemetrexed: a multitargeted antifolate. Clin Ther 27:1343-1382
18. Boles NC, Peddibhotla S, Chen AJ, Goodell MA, Rosen JM (2010) Chk1 haploinsufficiency results in anemia and defective erythropoiesis. PLoS One 5:e8581
19. Kummar S, Gutierrez ME, Gardner ER et al (2010) A phase I trial of UCN-01 and prednisone in patients with refractory solid tumors and lymphoma. Cancer Chemother Pharmacol 65:383-389
20. Cullen MH, Zatloukal P, Sörenson S et al (2008) A randomized phase III trial comparing standard and high-dose pemetrexed as second-line treatment in patients with locally advanced or metastatic non-small-cell lung cancer. Ann Oncol 19:939-945
21. Cohen MH, Johnson JR, Wang YC, Sridhara R, Pazdur R (2005) FDA drug approval summary: pemetrexed for injection (Alimta) for the treatment of non-small cell lung cancer. Oncologist 10:363-368